Content Disclaimer
Effective Date: March 1, 2026 Last Updated: March 1, 2026
The information provided on this website (drgoodenowedietarytherapeutics.com) is published by Dr. Goodenowe Dietary Therapeutics LLC (“DGDT”) for general informational and educational purposes only.
Not Medical Advice
Nothing on this Site constitutes medical advice, diagnosis, or treatment. The information presented here — including descriptions of investigational compounds, scientific research, clinical study results, and biological mechanisms — is not intended to replace the advice of a qualified healthcare professional. Always consult your physician or other qualified healthcare provider with any questions about a medical condition or treatment.
Do not start, stop, or change any medication or treatment based on information found on this Site.
Investigational Drug Status
ProdromeNeuro™ is an investigational drug candidate. It has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority as safe or effective for any indication. ProdromeNeuro™ is not available for purchase or prescription as a therapeutic.
Clinical Data Limitations
Clinical data presented on this Site is derived from a small, open-label, proof-of-concept study involving 22 participants. This study did not include a placebo control group. Results from this study are preliminary and exploratory in nature and do not constitute evidence of therapeutic efficacy or safety. Larger, randomized, controlled clinical trials are required to determine whether ProdromeNeuro™ is safe and effective.
Statistics, percentages, and outcomes presented on this Site should be interpreted in the context of these study limitations and not as evidence of a confirmed therapeutic benefit.
Scientific Content
The Site references published, peer-reviewed research as well as data from exploratory clinical studies. While we make reasonable efforts to present this information accurately, scientific knowledge is continually evolving. Findings referenced on this Site may be revised, updated, or contradicted by future research.
References to third-party research do not imply endorsement by the authors or institutions involved. The inclusion of citations to published research is intended to provide transparency regarding the scientific basis of DGDT’s investigational program.
Forward-Looking Statements
This Site contains forward-looking statements about planned regulatory filings, clinical trial timelines, and development goals. These statements reflect current expectations and are subject to significant risks and uncertainties. Actual results may differ materially. See our Forward-Looking Statements page for additional information.
No Endorsement
References to the Alzheimer’s Association, published journals, research institutions, or any other third-party organizations are for informational purposes only and do not imply endorsement of DGDT, ProdromeNeuro™, or any claims made on this Site by those organizations.
Relationship to Dietary Supplements
ProdromeNeuro™ as described on this Site is an investigational drug candidate being developed through FDA drug approval pathways. It is not a dietary supplement. During the transition period, a dietary supplement previously marketed under the ProdromeNeuro name may remain available through Prodrome Sciences Inc. That product is regulated under the Dietary Supplement Health and Education Act (DSHEA) and is distinct from the investigational compound described on this Site. See our About page for additional information.
Contact Us
If you have questions about the content on this Site, please contact us at:
Dr. Goodenowe Dietary Therapeutics LLC Email: info@drgoodenowe.com